medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2011, Number 1

Dermatología Cosmética, Médica y Quirúrgica 2011; 9 (1)

Sertaconazole cream 2%. Efficacy and safety in tinea pedis

Bonifaz A, Araiza J, Ramírez DS, Ponce ORM

Language: Spanish
References: 14
Page: 10-15
PDF size: 611.72 Kb.


ABSTRACT

Backgroud: Dermatophytoses are keratin tissue infections caused by dermatophytes. Tinea pedis is the most prevalent dermatophytose. Sertaconazole is a wide-spectrum, third generation imidazole, with a good efficacy and safety profile for tineas, pityriasis versicolor and candidiasis.
Objective: to assess the efficacy and safety of sertaconazole in tinea pedis.
Material and methods: 30 patients with clinical and mycologycal diagnosis of tinea pedis were treated with sertaconazole cream 2% topically once daily for 4 weeks, and follow up of 4 weeks.
Results: Two etiologic agents were isolated in this study: Trichophyton rubrum in 93%, and Trichophyton interdigitale in 7%. All patients completed the study: Clinical and mycologycal cure in 86%, improvement in 6.33%, and failure in 6.33%. No side effects were reported.
Conclusion: Sertaconazole is a third generation imidazole considered as a new treatment for tinea pedis, with high efficacy and excellent safety.


REFERENCES

  1. Sharma A, Saple DG, Surjushe A, Rao GR, Kura M, et al. “Efficacy and tolerability of sertaconazole nitrate 2% cream vs miconazole in patients with cutaneous dermatophytosis”. Mycoses. 2009. En prensa.

  2. Degreff H; Heeres J; Borgers M. “Antifungal azoles for skin disorders”. Expert Opin Ther Patents 2006; 16: 1235-1252.

  3. Arenas R, Padilla Desgarennes M, Bonifaz A, López Martínez R, Welsh- Lozano O, et al. Micosis superficiales. Tercera revisión del Consenso Nacional de prevención, diagnóstico y tratamiento. México, AMMM, AC, UNAM. 2005: 3-51.

  4. Bonifaz A. Micología Médica Básica. 3ª ed. México. McGraw-Hill. 2009:

  5. Kircik LH. “Observational evaluation of sertaconazole nitrate cream 2% in the treatment of pruritus related to tinea pedis”. Cutis 2009; 84: 279-283.

  6. Ribotsky BM. “Sertaconazole nitrate cream 2% for the treatment of tinea pedis”. Cutis 2009; 83: 274-277.

  7. Gupta AK, Ryder JE, Chow M, Cooper EA. “Dermatophytosis: The management of fungal infections”. Skinmed 2005; 4: 305-310.

  8. Pfaller MA, Sutton DA. “Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections”. Diagn Microbiol Infect Dis 2006; 56: 147-152.

  9. Wolff K; Allen-Johnson R. “Fungal Infections of the Skin and Hair”. En: Fitzpatrick´s Dermatology in General Medicine. 6a edición, McGraw Hill, 2009: 221-2217.

  10. Arenas R. “Dermatofitosis en México”. Rev Iberoam Micol 2002; 19: 63-67.

  11. Croxtall JD, Plosker GL. “Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology”. Drugs 2009; 69: 339-59.

  12. Savin R, Jorizzo J. “The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis”. Cutis 2006; 78: 268-74.

  13. Ghaninejad H, Gholami K, Hashemi P, Hajibabai M, Rahnar Z, et al. “Sertaconazole 2% cream vs Miconazole 2% cream for cutaneous mycoses: a doublé-blind clinical trial”. Clin Exp Dermatol 2009; 34: 837-39.

  14. Alomar C, Bassas S. Casas M. Crespo V, Ferrándiz C, et al. “Multi-centre double blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses”. Arneimittelforschung 1992; 42: 767-73.




2020     |     www.medigraphic.com